Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2018, Vol. 23 ›› Issue (4): 434-439.doi: 10.12092/j.issn.1009-2501.2018.04.012

Previous Articles     Next Articles

Effects of Yinaojieyu prescription on the kidney deficiency and liver depression of Parkinson's disease and the effect on DA, 5-HT and NE in serum

ZHOU Rong, LI Wei, HU Wanhua   

  1. Department of Neurology, Wenzhou Hospital of Traditional Chinese Medicine, Wenzhou 325000, Zhejiang, China
  • Received:2017-09-07 Revised:2017-10-13 Online:2018-04-26 Published:2018-04-13

Abstract:

AIM: To investigate the clinical efficacy of Yinaojieyu prescription in the treatment of depression of kidney deficiency and liver depression type Parkinson disease, and to evaluate the effects of Yinaojieyu prescription on serum DA, 5-HT and NE.  METHODS: Sixty patients with depression of kidney deficiency and liver depression type Parkinson disease were divided into the study group and the control group, 30 cases in each group. The control group was treated with paroxetine tablets. The study group was treated with Yinaojieyu prescription. Hamilton Depression Scale (HAMD) was used to evaluate the depressive state of patients. The Unified Parkinson Disease Rating Scale (UPDRS) was used to assess the condition of Parkinson's disease in the patient. WHO quality of life scale (WHOQOL-BREF) was used to assess the quality of life of patients with made. The levels of serum dopamine (DA), 5-serotonin (5-HT) and norepinephrine (NE) were measured before and after treatment in the two groups. RESULTS: The curative effect of the study group was higher than that of the control group, but the difference was not statistically significant (P>0.05); HAMD score and UPDRS score of the two groups after treatment were significantly decreased, while WHOQOL-BREF scores increased significantly (P<0.05); HAMD score and UPDRS score of the study group after treatment were lower than those of the control group; WHOQOL-BREF score was higher than that of the control group (P<0.05); The levels of DA, NE and 5-HT in two groups after treatment were significantly higher than those before treatment (P<0.05); after treatment, DA, NE, 5-HT of the study group increased as compared with the control group (P<0.05).No significant difference was observed of incidence of adverse reactions between the two groups (P>0.05). CONCLUSION: Yinaojieyu prescription is effective in treating Parkinson's disease with kidney deficiency and liver depression type, and can improve the levels of DA, 5-HT and NE.

Key words: Yinaojieyu prescription, Parkinson's disease, depression, DA, 5-HT, NE

CLC Number: